Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    12736280 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: marizomib;   Drug: low-dose dexamethasone
2 Unknown  Busulfan and Melphalan Conditioning in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: BUSULFEX®;   Drug: Alkeran®

Indicates status has not been verified in more than two years